PKU HealthCare (SZ:000788) Xin Lang Cai Jing·2026-01-14 02:39Core Viewpoint - North China Pharmaceutical has shown a positive stock performance with a year-to-date increase of 11.62% and a recent rise of 2.10% on January 14, 2025, indicating investor confidence in the company [1]. Financial Performance - For the period from January to September 2025, North China Pharmaceutical reported a revenue of 1.231 billion yuan, a year-on-year decrease of 19.76%, while the net profit attributable to shareholders increased by 4.31% to 136 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 183 million yuan, with 81.05 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 2.88% to 49,400, while the average number of tradable shares per person increased by 2.97% to 12,073 shares [2]. - Among the top ten circulating shareholders, Guangfa Quantitative Multi-Factor Mixed A (005225) is the sixth largest, holding 2.278 million shares as a new shareholder [3]. Market Activity - On January 14, 2025, North China Pharmaceutical's stock price reached 6.82 yuan per share, with a trading volume of 107 million yuan and a turnover rate of 2.66%, resulting in a total market capitalization of 4.065 billion yuan [1]. - The net inflow of main funds was 5.2776 million yuan, with significant buying activity from large orders amounting to 21.5419 million yuan, indicating strong market interest [1].